On June 10, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. that they have resigned from the Board. Mr. Boyd and Dr. Maher's resignations from the Board, effective June 10, 2022, did not arise from any disagreement with the Company, any member of the Board, or Company management regarding any matter related to the Company's operations, policies, practices, or otherwise, and will allow them to dedicate additional time to other aspects of the Master Fund's business.